Dopamine and schizophrenia--proof at last?
Harrison
P J
PJ
University Department of Psychiatry, Warneford Hospital, Oxford, UK.
D014150:Antipsychotic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000378:metabolism; D006801:Humans; D011759:Pyrrolidines / Q000378:metabolism; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism*; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism*; D015854:Up-Regulation / Q000187:drug effects
D014150:Antipsychotic Agents; D001549:Benzamides; D018492:Dopamine Antagonists; D011759:Pyrrolidines; D011954:Receptors, Dopamine; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D004298:Dopamine